Ï㽶ÊÓƵ

Laith F. Al-Rabadi
( out of 10 reviews )

Laith F. Al-Rabadi, MD

Languages spoken: English

Clinical Locations

Kidney & Liver Clinic

Kidney and Liver Clinic
Salt Lake City
801-585-6320

  • Dr. Al-Rabadi finished his undergraduate and medical training at Jordan Ï㽶ÊÓƵ of Science and Technology in 2007. Afterwards, he joined Edelman lab at Harvard-MIT Division of Health Sciences and Technology to study endothelial dysfunction in uremic milieu. Dr. Al-Rabdi finished his Internal Medicine training at Ï㽶ÊÓƵ of Iowa in 2013 then moved on to begin nephrology training at Boston Ï㽶ÊÓƵ-Boston Medical Center. He had the privilege to work with Dr. David Salant and developed special interest in Glomerular diseases. Dr. Al-Rabadi was also actively involved in teaching students and residents.

    His clinical interests include different aspects of nephrology particularly glomerular diseases, transplant, and peritoneal dialysis. He is involved in several clinical research projects and literature reviews.

    He established a unique collaboration with Dr. Laurence Beck at Boston Medical Center to initiate innovative projects related to membranous nephropathy (MN) pathogenesis with the goal of developing clinical and translational research and enhancing Ï㽶ÊÓƵ of Utah role as a destination site for MN. Dr. Beck is a world-renowned expert and an authority in MN and published extensively on the pathogenesis and biomarkers in MN. He also established a collaboration with Dr. Bernstein and from Moran Eye Center to perform clinical studies related to Alport syndrome (AS). He has been working closely with Dr. Gregory who, along with Dr. Atkins, has collected samples, clinical information and pedigrees of 130 families with X- linked AS. They also identified over 30 families with probable autosomal recessive AS based on patterns of inheritance. He evaluates many patients with AS at the kidney and the transplant clinic.

    He is motivated and committed to advance the field of glomerular diseases and Alport syndrome at the university of Utah

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Nephrology)

    Patient Rating

    4.7 /5
    ( out of 10 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    January 18, 2024
    UH HOSPITALS AND CLINICS

    have only the best to say about Faith Al-Rabadi he has been so helpful since my sickness reared its ugly head.

    June 29, 2023
    UH HOSPITALS AND CLINICS

    Me parece excelente mdico, muy cordial, atento, escucha al paciente, explica muy bien, se ve que se preocupa por el paciente.

    June 01, 2023
    UH HOSPITALS AND CLINICS

    Excellent care genuinely concerned

    June 01, 2023
    UH HOSPITALS AND CLINICS

    He is always personable, encouraging and optimistic. He provides clear concise information to explain my condition and current status. Unfortunately, like many excellent physicians, there are other demands for his time, and I will likely be seeing a different physician next time.

    April 18, 2023
    UH HOSPITALS AND CLINICS

    HAVE ALWAY BEEN VERY GRATEFULL FOR HIM SINCE DAY ONE HE IS VERY CARING AND HELPFULL

    April 15, 2023
    UH HOSPITALS AND CLINICS

    I feel confident that he is giving me the best care available for my kidney condition and have every confidence in him as a doctor

    November 25, 2022
    Ï㽶ÊÓƵ Hospital

    Good

    November 23, 2022
    Ï㽶ÊÓƵ Hospital

    They made me feel like I matter. That means a lot to me

    November 18, 2022
    Ï㽶ÊÓƵ Hospital

    I adore Dr. Al Ribaldi he is very caring, explains everything well and even said he'd see me on emergency notice.

  • Dr. Al-Rabadi finished his undergraduate and medical training at Jordan Ï㽶ÊÓƵ of Science and Technology in 2007. Afterwards, he joined Edelman lab at Harvard-MIT Division of Health Sciences and Technology to study endothelial dysfunction in uremic milieu. Dr. Al-Rabdi finished his Internal Medicine training at Ï㽶ÊÓƵ of Iowa in 2013 then moved on to begin nephrology training at Boston Ï㽶ÊÓƵ-Boston Medical Center. He had the privilege to work with Dr. David Salant and developed special interest in Glomerular diseases. Dr. Al-Rabadi was also actively involved in teaching students and residents.

    His clinical interests include different aspects of nephrology particularly glomerular diseases, transplant, and peritoneal dialysis. He is involved in several clinical research projects and literature reviews.

    He established a unique collaboration with Dr. Laurence Beck at Boston Medical Center to initiate innovative projects related to membranous nephropathy (MN) pathogenesis with the goal of developing clinical and translational research and enhancing Ï㽶ÊÓƵ of Utah role as a destination site for MN. Dr. Beck is a world-renowned expert and an authority in MN and published extensively on the pathogenesis and biomarkers in MN. He also established a collaboration with Dr. Bernstein and from Moran Eye Center to perform clinical studies related to Alport syndrome (AS). He has been working closely with Dr. Gregory who, along with Dr. Atkins, has collected samples, clinical information and pedigrees of 130 families with X- linked AS. They also identified over 30 families with probable autosomal recessive AS based on patterns of inheritance. He evaluates many patients with AS at the kidney and the transplant clinic.

    He is motivated and committed to advance the field of glomerular diseases and Alport syndrome at the university of Utah

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Pathology -Adjunct
    Academic Divisions Nephrology & Hypertension
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Nephrology)

    Education history

    Fellowship Nephrology - Boston Medical Center, Boston Ï㽶ÊÓƵ Fellow
    Residency Internal Medicine - Ï㽶ÊÓƵ of Iowa Hospitals and Clinics Resident
    Internship Internal Medicine - Ï㽶ÊÓƵ of Iowa Hospitals and Clinics Intern
    Internship General Surgery - King Abdullah Ï㽶ÊÓƵ Hospital Intern
    Internship General Medicine - Ministry of Health Transitional Internship
    Professional Medical Medicine - Jordan Ï㽶ÊÓƵ of Science and Technology M.B.B.S.

    Selected Publications

    Journal Article

    1. Al-Rabadi LF, Beck LH Jr (2022). Neuronal Proteins as Antigenic Targets in Membranous Nephropathy. Nephron, 147(8), 451-457. ()
    2. Tiffany N Caza1, Laith F Al-Rabadi2 and Laurence H Beck Jr (2021). How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy          . Front Immunol.
    3. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zitkiewicz BS (2021). Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet, 29(8), 1186-1197. ()
    4. Al-Rabadi LF, Caza T, Trivin-Avillach C, Rodan AR, Andeen N, Hayashi N, Williams B, Revelo MP, Clayton F, Abraham J, Lin E, Liou W, Zou CJ, Ramkumar N, Cummins T, Wilkey DW, Kawalit I, Herzog C, Storey A, Edmondson R, Sjoberg R, Yang T, Chien J, Merchant M, Arthur J, Klein J, Larsen C, Beck LH Jr (2021). Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. J Am Soc Nephrol, 32(7), 1666-1681. ()
    5. Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI (2020). Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. Oncologist, 26(2), 101-106. ()
    6. Khalighi MA, Al-Rabadi L, Chalasani M, Smith M, Kakani S, Revelo MP, Meehan SM (2018). Staphylococcal Infection-Related Glomerulonephritis With Cryoglobulinemic Features. Kidney Int Rep, 3(5), 1128-1134. ()
    7. Al-Rabadi L, Box T, Singhania G, Al-Marji C, Agarwal A, Hall I, Gordon CE, Tran H (2018). Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates. Hemodial Int, 22 Suppl 1, S45-S52. ()
    8. Shivanna S, Kolandaivelu K, Shashar M, Belghasim M, Al-Rabadi L, Balcells M, Zhang A, Weinberg J, Francis J, Pollastri MP, Edelman ER, Sherr DH, Chitalia VC (2016). The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol, 27(1), 189-201. ()
    9. Al-Rabadi L, Francis JM, Henderson J, Ghai S (2015). Proliferative glomerulonephritis with monoclonal immunoglobulin in renal allografts. Clin Kidney J, 8(6), 722-8. ()
    10. Chitalia VC, Murikipudi S, Indolfi L, Rabadi L, Valdez R, Franses JW, Edelman ER (2011). Matrix-embedded endothelial cells are protected from the uremic milieu. Nephrol Dial Transplant, 26(12), 3858-65. ()

    Review

    1. Caza T, Wijewardena C, Al-Rabadi L, Perl A (2022). Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis. [Review]. Transl Res. ()

    Book Chapter

    1. Al-Rabadi L (2019). Renal and Metabolic Disorders Related to Alcohol and Other Drug Use. In The ASAM Essentials of Addiction Medicine (3rd).

    Case Report

    1. Bansal S, Singhania N, Nukala CM, Singh AK, Al-Rabadi L (2021). Histoplasma stomatitis unveiled: Not all opportunistic infections get better after initiation of antiretroviral therapy. Clin Case Rep, 9(3), 1466-1468. ()
    2. Singhania N, Singhania G, Al-Rabadi L (2020). Acquired Reactive Perforating Collagenosis. Clin Exp Nephrol, 24(11), 1086-1087. ()
    3. Singhania N, Al-Odat R, Singh AK, Al-Rabadi L (2020). Intestinal necrosis after co-administration of sodium polystyrene sulfonate and activated charcoal. Clin Case Rep, 8(4), 722-724. ()
    4. Al-Rabadi L, Quillen K, Shashar M, Al Marji C, Jaberi A, Chitalia V, Henderson J, Salant D, Beck LH Jr (2017). Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. Kidney Int Rep, 3(2), 476-481. ()
    5. Al-Rabadi L, Ayalon R, Bonegio RG, Ballard JE, Fujii AM, Henderson JM, Salant DJ, Beck LH Jr (2016). Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report. Am J Kidney Dis, 67(5), 775-8. ()
    6. Aburizik A, Singh S, Al-Rabadi L, Blosser C (2014). Mistaken identity: normotensive scleroderma renal crisis.LID - 10.1136/bcr-2013-202566 [doi]LID - bcr2013202566 [pii]. BMJ Case Rep, 2014. ()

    Editorial

    1. Caza TN, Al-Rabadi LF (2022). What Can Mercury Teach Us About Membranous Nephropathy and Minimal Change Disease? Kidney Int Rep, 7(6), 1157-1160. ()

    Abstract

    1. Al-Odat R, Al-Rabadi L, Blosser C, Francis J (2014). Hypermagnesemia-induced hypothermia in a pregnant patient [Abstract]. ASN's 2014 Abstract Supplement of JASN.
    2. Al-Rabadi LF, Al-odat RT, Blosser CD (2012). Tacrolimus-Induced Thrombotic Microangiopathy Post Allogeneic Stem Cell Transplant [Abstract]. American Society of Nephrology, 23(Abstract Issue), PUB36, 902A.
    3. Erinle AO, Al-Rabadi LF, Sarker A, Gamilla-Crudo AK, Ishihara K, Beach R (2008). Seronegative Anti-GBM Disease; Clinical Dilemma in Management [Abstract]. American Society of Nephrology, PUB778, 19(Abstract Issue), 989A-990A.

    Other

    1. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zitkiewicz BS (2023). Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet. England. ()
    2. Savige J, Lipska-Zietkiewicz BS, Watson E, Hertz JM, Deltas C, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Renieri A, Storey H, Flinter F (2021). Guidelines for Genetic Testing and Management of Alport Syndrome. Clin J Am Soc Nephrol (17(1), pp. 143-154). United States. ()
    3. May RM, Cassol C, Hannoudi A, Larsen CP, Lerma EV, Haun RS, Braga JR, Hassen SI, Wilson J, VanBeek C, Vankalakunti M, Barnum L, Walker PD, Bourne TD, Messias NC, Ambruzs JM, Boils CL, Sharma SS, Cossey LN, Baxi PV, Palmer M, Zuckerman JE, Walavalkar V, Urisman A, Gallan AJ, Al-Rabadi LF, Rodby R, Luyckx V, Espino G, Santhana-Krishnan S, Alper B, Lam SG, Hannoudi GN, Matthew D, Belz M, Singer G, Kunaparaju S, Price D, Chawla S, Rondla C, Abdalla MA, Britton ML, Paul S, Ranjit U, Bichu P, Williamson SR, Sharma Y, Gaspert A, Grosse P, Meyer I, Vasudev B, El Kassem M, Velez JCQ, Caza TN (2021). A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int (100(6), pp. 1303-1315). United States. ()
    4. Huang Z, Liu S, Tang A, Al-Rabadi L, Henkemeyer M, Mimche PN, Huang Y (2021). Key role for EphB2 receptor in kidney fibrosis. Clin Sci (Lond) (135(17), pp. 2127-2142). England. ()
    5. Lazaro-Guevara J, Fierro-Morales J, Wright AH, Gunville R, Simeone C, Frodsham SG, Pezzolesi MH, Zaffino CA, Al-Rabadi L, Ramkumar N, Pezzolesi MG (2021). Targeted Next-Generation Sequencing Identifies Pathogenic Variants in Diabetic Kidney Disease. Am J Nephrol (52(3), pp. 239-249). Switzerland. ()

  • News & Podcasts

    News